These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38416391)

  • 1. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study.
    Chandran V; Bessette L; Thorne C; Sheriff M; Rahman P; Gladman DD; Anwar S; Jelley J; Gaudreau AJ; Chohan M; Sampalis JS
    Rheumatol Ther; 2024 Apr; 11(2):443-455. PubMed ID: 38416391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
    Mease PJ; Kavanaugh A; Ogdie A; Wells AF; Bergman M; Gladman DD; Richter S; Teng L; Jardon S; Smolen JS
    J Rheumatol; 2022 Jul; 49(7):694-699. PubMed ID: 35428720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Young P; Fallon L; Mundayat R; Dina O; Blachley T; Middaugh N; Ogdie A
    Rheumatol Ther; 2024 Apr; 11(2):313-329. PubMed ID: 38252211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
    Gratacós-Masmitja J; Beltrán Catalán E; Álvarez Vega JL; Urruticoechea-Arana A; Fito C; Maceiras F; Belzunegui Otano JM; Fernández Melón J; Chamizo Carmona E; Abad Hernández MÁ; Ros Vilamajó I; Castro Oreiro S; Pascual Alfonso E; Torre Alonso JC;
    Reumatol Clin (Engl Ed); 2024 Jan; 20(1):24-31. PubMed ID: 38233009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.
    Sfikakis PP; Vassilopoulos D; Katsifis G; Vosvotekas G; Dimitroulas T; Sidiropoulos P; Vounotrypidis P; Bogdanos DP; Georgountzos AΙ; Bounas AG; Georgiou P; Gazi S; Kataxaki E; Liossis SN; Theodorou E; Papagoras C; Theotikos E; Vlachoyiannopoulos P; Voulgari PV; Kekki A; Antonakopoulos N; Boumpas DT
    Rheumatol Int; 2023 May; 43(5):889-902. PubMed ID: 36856816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.
    de Vlam K; Toukap AN; Kaiser MJ; Vanhoof J; Remans P; Van den Berghe M; Di Romana S; Van den Bosch F; Lories R
    Adv Ther; 2022 Feb; 39(2):1055-1067. PubMed ID: 34977986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
    Mease PJ; Gladman DD; Ogdie A; Coates LC; Behrens F; Kavanaugh A; McInnes I; Queiro R; Guerette B; Brunori M; Teng L; Smolen JS
    Arthritis Care Res (Hoboken); 2020 Jun; 72(6):814-821. PubMed ID: 31909868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.
    Jullien D; Richard MA; Halioua B; Bessette C; Derancourt C; Bouloc A
    Dermatol Ther (Heidelb); 2023 Jun; 13(6):1361-1376. PubMed ID: 37204608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study).
    Samanta J; Naidu G; Chattopadhyay A; Basnet A; Narang T; Dhir V; Dogra S; Jain S; Sharma A
    Rheumatol Int; 2023 May; 43(5):841-848. PubMed ID: 36961603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs.
    Khraishi MM; Remple VP; Silverberg S; Stewart JC; Florica B; Bessette L
    J Rheumatol; 2022 May; 49(5):454-464. PubMed ID: 35033999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
    Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
    Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry.
    Rahman P; Arendse R; Khraishi M; Sholter D; Sheriff M; Rampakakis E; Lehman AJ; Nantel F
    BMJ Open; 2020 Aug; 10(8):e036245. PubMed ID: 32792436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials.
    Mease PJ; Gladman DD; Kavanaugh A; McGonagle D; Nash P; Guerette B; Nakasato P; Brunori M; Teng L; McInnes IB
    Rheumatol Ther; 2021 Dec; 8(4):1677-1691. PubMed ID: 34536218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Ogdie A; Tesser J; Shiff NJ; Lin I; Chakravarty SD; Kelleman M; Dodge R; McLean RR; Broadwell A; Kavanaugh A; Merola JF
    Rheumatol Ther; 2023 Dec; 10(6):1479-1501. PubMed ID: 37597159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual Disease Burden in Patients With Axial Spondyloarthritis and Psoriatic Arthritis Despite Low Disease Activity States in a Multiethnic Asian Population.
    Liu V; Fong W; Kwan YH; Leung YY
    J Rheumatol; 2021 May; 48(5):677-684. PubMed ID: 33132217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.